FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Trial
- MIRASOL
- Drug
- Elahere (mirvetuximab soravtansine-gynx) · Anti-FOLR1 antibody-drug conjugate
- Condition
- Gynecologic